MEA measurements using the Maestro MEA System

Drug-induced effects on the cell electrophysiology is detected by measuring the extracellular field potential (EFP) of hiPSC-derived cardiomyocytes. EFPs are obtained noninvasively using microelectrode array (MEA) technology without the need for dyes. The multi-well Maestro MEA system (Axion BioSystems) enables EFP recordings in a range of multi-well plates.

Application protocol

Ncardia supplies human iPSC-derived cardiomyocytes optimized for use with the Maestro MEA System. Together these technologies enable detailed electrophysiological detection of potential cardioactive and proarrhythmic effects of test compounds in 48- and 96-well plate formats. The result is a highly relevant in vitro assay platform for studying cardiac safety or efficacy profile of compounds during drug development.

Application note

Cardiac safety assessment using hiPSC-derived cardiomyocytes in combination with the Maestro MEA system

Case studies were performed to assess the effects of cardioactive compounds on the electrophysiology of Pluricyte Cardiomyocytes using the Maestro MEA system. Pluricyte Cardiomyocytes show the expected pharmacological responses to reference compounds in a reproducible manner.